Crinetics Pharmaceuticals Financials
Crinetics Pharmaceuticals (CRNX) reported $7.7M in revenue for fiscal year 2025, up 640.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Crinetics remains an equity-funded development-stage business, with research spending and overhead—not product sales—determining cash consumption.
FY2025 free cash burn was nearly identical to operating cash burn because capex was only$5.8M against-$377.9M of operating outflow. That makes this a cash-intensive research platform but a capital-light physical business, with spending pressure coming from programs and headcount rather than equipment.
Short-term liquidity is still substantial: current assets of
Commercial scale has not arrived: FY2025 revenue was only
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Crinetics Pharmaceuticals's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Crinetics Pharmaceuticals scores 38.02, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($9.0B) relative to total liabilities ($134.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Crinetics Pharmaceuticals passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Crinetics Pharmaceuticals reported a net loss of $465.3M while operations used $377.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Crinetics Pharmaceuticals generated $7.7M in revenue in fiscal year 2025. This represents an increase of 640.7% from the prior year.
Crinetics Pharmaceuticals's EBITDA was -$512.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 52.6% from the prior year.
Crinetics Pharmaceuticals reported -$465.3M in net income in fiscal year 2025. This represents a decrease of 55.9% from the prior year.
Crinetics Pharmaceuticals earned -$4.95 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 34.1% from the prior year.
Cash & Balance Sheet
Crinetics Pharmaceuticals recorded an outflow of $383.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 63.9% from the prior year.
Crinetics Pharmaceuticals held $101.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Crinetics Pharmaceuticals's gross margin was 86.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 14.0 percentage points from the prior year.
Crinetics Pharmaceuticals's ROE was -46.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 24.4 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Crinetics Pharmaceuticals invested $332.1M in research and development in fiscal year 2025. This represents an increase of 38.3% from the prior year.
Crinetics Pharmaceuticals invested $5.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 49.9% from the prior year.
Not reported for fiscal year 2025.
CRNX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42.2M | $7.7M+640.7% | $1.0M-74.1% | $4.0M-15.3% | $4.7M+339.4% | $1.1M+1418.3% | $71K-94.0% | $1.2M-50.9% | $2.4M+18.7% | $2.0M+247.2% | $589K |
| Cost of Revenue | N/A | $1.1M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $6.6M+537.2% | $1.0M-74.1% | $4.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $375.4M | $332.1M+38.3% | $240.2M+42.5% | $168.5M+29.4% | $130.2M+54.6% | $84.3M+47.8% | $57.0M+37.3% | $41.5M+69.6% | $24.5M+165.1% | $9.2M+81.0% | $5.1M |
| SG&A Expenses | $214.4M | $191.3M+91.8% | $99.7M+71.7% | $58.1M+37.0% | $42.4M+72.9% | $24.5M+36.1% | $18.0M+33.3% | $13.5M+103.0% | $6.7M+243.4% | $1.9M+26.5% | $1.5M |
| Operating Income | -$549.1M | -$516.8M-52.5% | -$338.9M-52.2% | -$222.6M-32.6% | -$167.9M-55.9% | -$107.7M-43.7% | -$75.0M-39.2% | -$53.8M-87.5% | -$28.7M-214.6% | -$9.1M-51.0% | -$6.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $8K-27.3% | $11K |
| Income Tax | N/A | $180K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$501.6M | -$465.3M-55.9% | -$298.4M-39.1% | -$214.5M-30.9% | -$163.9M-52.3% | -$107.6M-45.8% | -$73.8M-46.4% | -$50.4M-86.0% | -$27.1M-196.1% | -$9.2M-52.1% | -$6.0M |
| EPS (Diluted) | — | -$4.95-34.1% | -$3.690.0% | -$3.69-17.1% | -$3.15-12.5% | -$2.80-15.7% | -$2.42 | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CRNX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.1B-21.5% | $1.4B+125.8% | $635.4M+80.4% | $352.2M+0.3% | $351.0M+91.3% | $183.4M+40.7% | $130.4M-23.9% | $171.4M+999.0% | $15.6M | N/A |
| Current Assets | $1.0B-23.8% | $1.4B+139.6% | $574.2M+66.3% | $345.2M+0.1% | $344.7M+94.2% | $177.5M+43.9% | $123.3M-26.0% | $166.7M+999.1% | $15.2M | N/A |
| Cash & Equivalents | $101.5M-61.6% | $264.5M+381.9% | $54.9M+68.0% | $32.7M-83.7% | $200.7M+115.6% | $93.1M+130.8% | $40.3M-10.3% | $45.0M+216.9% | $14.2M+16.8% | $12.2M |
| Inventory | $2.0M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $592K | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $134.2M+22.2% | $109.8M+14.1% | $96.2M+168.5% | $35.8M+88.0% | $19.1M+31.3% | $14.5M+9.7% | $13.2M+18.3% | $11.2M-63.5% | $30.6M | N/A |
| Current Liabilities | $85.1M+42.5% | $59.7M+35.8% | $43.9M+58.5% | $27.7M+73.3% | $16.0M+52.5% | $10.5M+25.8% | $8.3M+5.2% | $7.9M+783.5% | $897K | N/A |
| Total Equity | $992.1M-25.1% | $1.3B+145.7% | $539.1M+70.4% | $316.3M-4.7% | $331.9M+96.5% | $168.9M+44.2% | $117.1M-26.9% | $160.2M+1166.6% | -$15.0M-142.1% | -$6.2M |
| Retained Earnings | -$1.4B-48.9% | -$952.1M-45.6% | -$653.7M-48.8% | -$439.2M-59.6% | -$275.3M-64.2% | -$167.6M-78.7% | -$93.8M-116.2% | -$43.4M-166.7% | -$16.3M | N/A |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
CRNX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$422.5M | -$377.9M-64.2% | -$230.2M-36.5% | -$168.6M-46.3% | -$115.2M-30.0% | -$88.6M-42.8% | -$62.0M-33.7% | -$46.4M-138.4% | -$19.5M-105.3% | -$9.5M-73.4% | -$5.5M |
| Capital Expenditures | $2.7M | $5.8M+49.9% | $3.8M-18.0% | $4.7M+183.1% | $1.7M+279.8% | $436K+134.4% | $186K-62.2% | $492K-53.5% | $1.1M+248.4% | $304K+60.0% | $190K |
| Free Cash Flow | -$425.2M | -$383.7M-63.9% | -$234.0M-35.1% | -$173.3M-48.3% | -$116.9M-31.3% | -$89.0M-43.1% | -$62.2M-32.7% | -$46.9M-128.4% | -$20.5M-109.7% | -$9.8M-72.9% | -$5.7M |
| Investing Cash Flow | -$4.2M | $173.9M+130.3% | -$574.8M-186.8% | -$200.4M-15.2% | -$174.0M-208.0% | -$56.5M-26129.0% | $217K-99.5% | $41.7M+134.9% | -$119.5M-39195.4% | -$304K-60.0% | -$190K |
| Financing Cash Flow | $427.9M | $40.6M-96.0% | $1.0B+159.3% | $391.2M+220.8% | $122.0M-51.7% | $252.7M+120.5% | $114.6M+170901.5% | $67K-100.0% | $170.2M+1339.6% | $11.8M+22407.5% | -$53K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CRNX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.0%-14.0pp | 100.0%0.0pp | 100.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | -446.3% | -1026.2% |
| Net Margin | -6046.0% | -28719.9% | -5345.1% | -3460.0% | -9981.4% | -103960.6% | -4226.5% | -1116.8% | -447.8% | -1021.9% |
| Return on Equity | -46.9%-24.4pp | -22.5%+17.3pp | -39.8%+12.0pp | -51.8%-19.4pp | -32.4%+11.3pp | -43.7%-0.7pp | -43.0%-26.1pp | -16.9% | N/A | N/A |
| Return on Assets | -41.3%-20.5pp | -20.8%+13.0pp | -33.8%+12.8pp | -46.5%-15.9pp | -30.6%+9.6pp | -40.2%-1.6pp | -38.7%-22.8pp | -15.8%+42.9pp | -58.7% | N/A |
| Current Ratio | 12.32-10.7x | 23.04+10.0x | 13.07+0.6x | 12.45-9.1x | 21.55+4.6x | 16.92+2.1x | 14.79-6.2x | 21.03+4.1x | 16.91 | N/A |
| Debt-to-Equity | 0.14+0.1x | 0.08-0.1x | 0.18+0.1x | 0.11+0.1x | 0.060.0x | 0.090.0x | 0.110.0x | 0.07 | N/A | N/A |
| FCF Margin | -4985.5% | -22525.3% | -4318.1% | -2467.0% | -8258.3% | -87623.9% | -3929.0% | -845.1% | -478.4% | -960.6% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Crinetics Pharmaceuticals Ranks
Frequently Asked Questions
What is Crinetics Pharmaceuticals's annual revenue?
Crinetics Pharmaceuticals (CRNX) reported $7.7M in total revenue for fiscal year 2025. This represents a 640.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Crinetics Pharmaceuticals's revenue growing?
Crinetics Pharmaceuticals (CRNX) revenue grew by 640.7% year-over-year, from $1.0M to $7.7M in fiscal year 2025.
Is Crinetics Pharmaceuticals profitable?
No, Crinetics Pharmaceuticals (CRNX) reported a net income of -$465.3M in fiscal year 2025.
What is Crinetics Pharmaceuticals's EBITDA?
Crinetics Pharmaceuticals (CRNX) had EBITDA of -$512.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Crinetics Pharmaceuticals's gross margin?
Crinetics Pharmaceuticals (CRNX) had a gross margin of 86.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Crinetics Pharmaceuticals's return on equity (ROE)?
Crinetics Pharmaceuticals (CRNX) has a return on equity of -46.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Crinetics Pharmaceuticals's free cash flow?
Crinetics Pharmaceuticals (CRNX) recorded an outflow of $383.7M in free cash flow during fiscal year 2025. This represents a -63.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Crinetics Pharmaceuticals's operating cash flow?
Crinetics Pharmaceuticals (CRNX) recorded an outflow of $377.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Crinetics Pharmaceuticals's total assets?
Crinetics Pharmaceuticals (CRNX) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Crinetics Pharmaceuticals's capital expenditures?
Crinetics Pharmaceuticals (CRNX) invested $5.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Crinetics Pharmaceuticals spend on research and development?
Crinetics Pharmaceuticals (CRNX) invested $332.1M in research and development during fiscal year 2025.
What is Crinetics Pharmaceuticals's current ratio?
Crinetics Pharmaceuticals (CRNX) had a current ratio of 12.32 as of fiscal year 2025, which is generally considered healthy.
What is Crinetics Pharmaceuticals's debt-to-equity ratio?
Crinetics Pharmaceuticals (CRNX) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Crinetics Pharmaceuticals's return on assets (ROA)?
Crinetics Pharmaceuticals (CRNX) had a return on assets of -41.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Crinetics Pharmaceuticals's Altman Z-Score?
Crinetics Pharmaceuticals (CRNX) has an Altman Z-Score of 38.02, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Crinetics Pharmaceuticals's Piotroski F-Score?
Crinetics Pharmaceuticals (CRNX) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Crinetics Pharmaceuticals's earnings high quality?
Crinetics Pharmaceuticals (CRNX) reported a net loss of $465.3M while operations used $377.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals (CRNX) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.